2005 Fiscal Year Final Research Report Summary
Postmenopausal hormone replacement therapy for prevention of cardiovascular disease.
| Project/Area Number |
16591665
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Aichi Medical University (2005)
Kochi University (2004) |
|---|
Principal Investigator |
WAKATSUKI Akihiko Aichi Medical University, Dept.of Obstetrics & Gynecology, Professor, 医学部, 教授 (90191717)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Keywords | Postmenopausal women / Lower dose of oral estrogen / Vascular inflammatory markers / LDL particle size / Cardiovascular disease |
|---|
| Research Abstract |
(Objectives) Oral administration of conjugated equine estrogen (CEE) at a dosage of 0.625 mg increases plasma triglycerides and decreases the size of LDL particles that are more susceptible to oxidation. In addition, oral CEE at a dosage of 0.625 mg increases vascular inflammatory markers. In the present study, we investigated whether lower dosage of oral estrogen can eliminate the adverse effects of high-dosage oral ERT on the size and oxidative susceptibility of LDL or vascular inflammatory markers in postmenopausal women.
(Methods and Results) Postmenopausal women received no treatment or were treated with oral conjugated equine estrogen 0.625 mg or 0.3125 mg daily for 3 months. CEE at a dose of 0.625 mg significantly increased plasma triglyceride concentrations and decreased LDL diamter, but the concentrations of LDL-derived thiobarbituric acid reactive substance (TBARS) that represents susceptibility of LDL oxidation did not change. CEE at a dose of 0.625 mg significantly increased plasma concentrations of CRP, serum amyloid A protein (SAA), and matrix metalloproteinase (MMP)-3, but significantly decreased tissue inhibitor of MMP (TIMP)-1 concentrations. In contrast, 0.3125 mg of CEE did not affect plasma triglyceride concentrations or LDL diameter, and significantly decreased LDL-derived TBARS concentrations. In addition, this dose of CEE did not affect inflammatory markers.
(Conclusion) Adverse effects of high-dosage oral estrogen such as LDL size and vascular inflammatory markers can be reversed by the administration of lower dose estrogen.
|
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] A novel type hypertriglyceridemia observed in FLS mice.2003
Author(s)
Takahashi M, Saibara T, Nemoto Y, Ono M, Akisawa N, Iwasaki S, Toda K, Ogawa Y, Wakatsuki A, Inagaki S, Onishi S.
-
Journal Title
Description
「研究成果報告書概要(和文)」より
-
